Thor Medical ASA-logo

Thor Medical ASA

Følg pressemeldinger fra Thor Medical ASA

Registrer deg med din e-postadresse for å få de nyeste sakene fra Thor Medical ASA på e-post fortløpende. Du kan melde deg av når som helst.

Thor Medical ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’. 

To learn more, visit  www.thormedical.no.

Oslo Børs
Vis Alt
År
Vis Alt

Thor Medical ASA: Completion of annual general meeting24.4.2025 15:03:03 CEST | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

Oslo, Norway, 24 April 2025 The annual general meeting in Thor Medical ASA (the "Company") was held today, 24 April 2025. All items on the agenda were approved in accordance with the notice. The minutes are attached hereto and are also available on https://www.thormedical.no/. DISCLOSURE REGULATION This information is required to be disclosed under Section 5-12 of the Securities Trading Act. CONTACTS Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com ABOUT THOR MEDICAL ASA Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'. To learn more, visit www.t

2 vedlegg

Flagging Thor Medical ASA 11 April 202511.4.2025 18:27:35 CEST | Thor Medical ASA | Major shareholding notifications

Oslo, 11 April 2025 Ludvik Sandnes, Chairman of the Board at Thor Medical ASA (the "Company"), has received proxies without voting instructions to vote for a total of 15,786,906 shares at the Company's Annual General Meeting on 24 April 2025, representing approx. 5.00 percent of all shares in the Company. Additionally, Sandnes has received proxies with voting instructions to vote for a total of 3,046,978 shares at the Company's Annual General Meeting on 24 April 2025, representing approx. 0.97 percent of all shares in the Company. Furthermore, Sandnes owns 626,489 shares, representing approx. 0.20 percent of all shares issued in the Company, as well as 300,000 shares, representing approx. 0.10 percent of all issued shares in the Company through Ekornhuset AS. Sandnes will be able to cast votes at the Annual General Meeting for a total of 19,760,375 shares, representing approx. 6.27 percent of all issued shares in the Company. The received proxies are valid only for the aforementioned G

1 vedlegg

Thor Medical ASA: Notification of trade for close associates of primary insider4.4.2025 10:52:15 CEST | Thor Medical ASA | Mandatory notification of trade primary insiders

Oslo, Norway, 4 April 2025: Scatec Innovation AS, a close associate of board member of Thor Medical ASA John Andersen, has today acquired 354,453 shares in Thor Medical ASA from its controlled subsidiary, Scatec Invest IV AS, also a close associate of John Andersen, with a price of NOK 2.388 per share, reflecting the last 5 days’ vwap for the share. The transaction is an internal group transaction to settle balances between the parent company and its subsidiary. Primary insider notifications pursuant to the market abuse regulation article 19 are attached. This information is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 5 and the Norwegian Securities Trading Act section 5-12. Contacts Gisle Bjørnstad, CFO, Scatec Innovation AS, +47 95142892, gisle.bjornstad@scatec.no ABOUT THOR MEDICAL ASA Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process

2 vedlegg

Thor Medical ASA - Notice of Annual General Meeting on 24 April 20253.4.2025 08:38:16 CEST | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

3 April 2025: Notice is given that the Annual General Meeting of Thor Medical ASA will be held on 24 April 2025, at 14:00 hours CEST at Advokatfirmaet Selmer, Ruseløkkveien 14, 0251 Oslo. The full notice and appendices are attached. The notice and the documents to which it refers are also available on www.thormedical.com. DISCLOSURE REGULATION This information is required to be disclosed under Section 5-12 of the Securities Trading Act. CONTACTS Brede Ellingsæter, CFOO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com ABOUT THOR MEDICAL ASA Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ti

5 vedlegg

Thor Medical ASA publishes Annual report 202428.3.2025 07:00:00 CET | Thor Medical ASA | Annual financial and audit reports

Oslo, 28 March 2025: Thor Medical ASA has today published its annual report, including the sustanability statement, for the financial year ended 31 December 2024, as well as the Renumeration report for 2024. The annual report and remuneration report is available on Thor Medicals's website: www.thormedical.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

4 vedlegg

Thor Medical makes final investment decision for AlphaOne – ready for commercial production in 202625.3.2025 16:46:27 CET | Thor Medical ASA | Non-regulatory press releases

Oslo, 25 March 2025: The Board of Directors of Thor Medical ASA has taken the final investment decision (FID) to go ahead with AlphaOne, its first commercial scale plant for production of alpha-emitters for use in next-generation precision cancer treatment. At an estimated capex investment of NOK 200 million, AlphaOne is expected to start production in the third quarter 2026 to meet the rapidly growing global demand for radioisotopes.

1 vedlegg

Thor Medical ASA interim and full-year 2024 results – closing in on commercial launch26.2.2025 07:00:01 CET | Thor Medical ASA | Half yearly financial reports and audit reports / limited reviews

Oslo, 26 February 2024: Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, today announced interim results and preliminary full-year 2024 results. The company is still in a pre-commercial phase but expects to execute a final investment decision for its AlphaOne plant in March 2025 for start-up in 2026. The company will begin delivering limited commercial volumes from its existing pilot plant already this year.

3 vedlegg

Invitation to presentation of Thor Medical ASA's second half and full year results 202420.2.2025 08:00:00 CET | Thor Medical ASA | Non-regulatory press releases

Thor Medical ASA will release its second half and full year results 2024 on Wednesday 26 February 2025 at 07:00 am (CEST). A presentation of the results followed by a Q&A session will be held on the same day at 08:00 am at Carnegie's offices at Aker Brygge, Fjordalleen 16, and through a live webcast. The presentation and the Q&A session can be followed through a live webcast from our website www.thormedical.com or using the following link: Thor Medical Webcast 2H 2024.

1 vedlegg

Thor Medical ASA: Share capital increase in relation to Subsequent Offering registered10.2.2025 09:25:55 CET | Thor Medical ASA | Total number of voting rights and capital

Oslo, Norway, 10 February 2025: Reference is made to stock exchange announcements by Thor Medical ASA (the "Company") on 24 January 2025 regarding the final results of a subsequent offering (the "Subsequent Offering"), where a total of 10,519,746 new shares in the Company were allocated and resolved issued by the board of directors. The share capital increase relating to the Subsequent Offering is now registered with the Norwegian Register of Business Enterprises. The Company's share capital is after the registration NOK 62,881,704.20, divided into 314,408,521 shares. Each share has a nominal value of NOK 0.20 and represents one vote in the Company's general meeting. DISCLOSURE REGULATION This information is required to be disclosed under Section 5-12 of the Securities Trading Act. CONTACTS Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no ABOUT THOR MEDICAL ASA Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emit

1 vedlegg

Thor Medical ASA: Notification of trade for close associate of primary insider24.1.2025 20:17:31 CET | Thor Medical ASA | Mandatory notification of trade primary insiders

Oslo, Norway, 24 January 2025: Jorunn Sandnes, a close associate of chairperson of the board of Thor Medical ASA, Ludvik Sandnes, has been allocated 50,000 shares in the subsequent offering of Thor Medical ASA at the subscription price of NOK 2.5 per share. Primary insider notifications pursuant to the market abuse regulation article 19 are attached. This information is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 19 and the Norwegian Securities Trading Act section 5-12. ABOUT THOR MEDICAL ASA Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'. To le

2 vedlegg

Thor Medical ASA: Final results of the Subsequent Offering24.1.2025 20:00:47 CET | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, 24 January 2025. Reference is made to the announcement by Thor Medical ASA (the "Company") on 13 January 2025 regarding commencement of the subscription period in the subsequent offering of up to 11,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 2.50 per share (the "Subsequent Offering"). The subscription period in the Subsequent Offering (the "Subscription Period") expired today, on 24 January 2025 at 12:30 hours (CET). By the end of the Subscription Period, the Company had received valid subscriptions

1 vedlegg

Thor Medical ASA: The Subscription Period in the Subsequent Offering ends today at 12:30 CET24.1.2025 07:00:00 CET | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, 24 January 2025. Reference is made to the announcement by Thor Medical ASA (the "Company") on 13 January 2025 regarding commencement of the subscription period in the subsequent offering of up to 11,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 2.50 per share (the "Subsequent Offering"). The subscription period for the Subsequent Offering (the “Subscription Period”) will expire today, 24 January 2025, at 12:30 hours (CET). Correctly completed subscription forms must be received by the Manager (as define

1 vedlegg

Thor Medical ASA: Notification of trade for close associate of primary insider15.1.2025 14:01:01 CET | Thor Medical ASA | Meldepliktig handel for primærinnsidere

Oslo, Norway, 15 January 2025: Ekornhuset AS, a close associate of chairperson of the board of Thor Medical ASA, Ludvik Sandnes, has today acquired 200,000 shares in Thor Medical ASA at a price of NOK 2.491 per share. Primary insider notifications pursuant to the market abuse regulation article 19 are attached. This information is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 5 and the Norwegian Securities Trading Act section 5-12.

2 vedlegg

Thor Medical ASA: Disclosure of large shareholdings15.1.2025 11:01:37 CET | Thor Medical ASA | Flagging

Oslo, Norway, 15 January 2025: Reference is made to the stock exchange announcement by Thor Medical ASA (the "Company") on 11 December 2024 regarding a private placement of new shares to be issued by the Company (the "Private Placement") and stock exchange announcement by the Company on 6 January 2025 regarding disclosure of share lending. In connection with the registration of the share capital increase pertaining to tranche 2 ("Tranche 2") of the Private Placement, the manager has redelivered a total of 11,396,380 borrowed shares to Scatec Innovation AS, close associate of primary insider of the Company John Andersen. During the term of the loan, and prior to the redelivery of the shares, Scatec Innovation AS' shareholding in the Company was reduced to 54,605,876, equivalent to approx. 19.5% of the issued share capital and votes. Upon redelivery of the borrowed shares and delivery of the 12,000,000 new shares allocated to Scatec Innovation AS in Tranche 2, Scatec Innovation AS' holdi

2 vedlegg

Thor Medical ASA: Share capital increase in relation to Tranche 2 of the Private Placement is registered15.1.2025 10:31:39 CET | Thor Medical ASA | Changes in the rights attaching to the classes of shares or securities

Oslo, Norway, 15 January 2025: Reference is made to stock exchange announcements by Thor Medical ASA (the "Company") on 12 December 2024 regarding the completion of a private placement of a total of 63,000,000 new shares (the "Offer Shares") in the Company raising a total of NOK 157.5 million (the "Private Placement"). The share capital increase relating to tranche 2 of the Private Placement ("Tranche 1"), consisting of 23,396,380 Offer Shares is now registered with the Norwegian Register of Business Enterprises. The Company's share capital is after the registration NOK 60,777,755, divided into 303,888,775 shares. Each share has a nominal value of NOK 0.20 and represents one vote in the Company's general meeting. DISCLOSURE REGULATION This information is required to be disclosed under Section 5-12 of the Securities Trading Act. CONTACTS Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no ABOUT THOR MEDICAL ASA Thor Medical is an emerging supplier

1 vedlegg

Thor Medical ASA: Commencement of the subscription period for the subsequent offering13.1.2025 07:00:01 CET | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, 13 January 2025. Reference is made to the announcement by Thor Medical ASA (the "Company") on 10 January 2025 regarding the approval of a prospectus and the launch of a subsequent offering (the "Subsequent Offering") of up to 11,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 2.50 per share (the "Subscription Price") with gross proceed of up to NOK 27.5 million. The Subscription Period (as defined below) for the Subsequent Offering commences today, 13 January 2025 at 09:00 (CET) and expires on 24 January

1 vedlegg

Thor Medical ASA: Approval of prospectus and launch of subsequent offering10.1.2025 13:30:55 CET | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, 10 January 2025. Reference is made to the announcement by Thor Medical ASA (the "Company") on 12 December 2024, regarding the successful placement of a private placement in the Company raising gross proceeds of NOK 157.5 million (the "Private Placement") and a potential subsequent offering of up to 11,000,000 new shares (the "Offer Shares") at a at a subscription price of NOK 2.50 per share (the "Subsequent Offering"). The subscription price is equal to the subscription price in the Private Placement. Approval and publication of the prospectu

1 vedlegg

Thor Medical secures NOK 90 million loan from Innovation Norway, ensuring full financing of AlphaOne7.1.2025 07:45:01 CET | Thor Medical ASA | Non-regulatory press releases

Oslo, 7 January 2025: Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, has received a NOK 90 million loan facility commitment from Innovation Norway. The company's first commercial-scale plant AlphaOne is hence fully funded, with the final investment decision scheduled by the end of the first quarter 2025.

1 vedlegg

Thor Medical ASA: Disclosure of large shareholding – share lending6.1.2025 15:00:27 CET | Thor Medical ASA | Flagging

Oslo, Norway, 6 January 2025: Reference is made to the stock exchange announcements by Thor Medical ASA (the "Company") on 11 December 2024 regarding a private placement of new shares to be issued by the Company (the "Private Placement") and stock exchange announcement on 6 January 2025 regarding the completion of an extraordinary general meeting. The extraordinary general meeting resolved to issue the 23,396,380 new shares (the "Offer Shares") in tranche 2 ("Tranche 2") of the Company's completed Private Placement. As part of the settlement arrangements for the Private Placement, the Company has entered into a share lending agreement (the "Share Lending Agreement") with Carnegie AS (the "Manager") and Scatec Innovation AS. Under the Share Lending Agreement, Scatec Innovation AS has agreed to lend existing and unencumbered shares in the Company, already being traded on Euronext Oslo Børs, to the Manager for the settlement of Tranche 2 of the Private Placement. The borrowed shares will

2 vedlegg
  • 1
  • 2
  • 3
  • 4
  • Siste
  • >>

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’. 

To learn more, visit  www.thormedical.no.

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye